Moderna (MRNA) FY2025 Earnings Quality Report

Grade: F — Major red flags

Framework: Schilit *Financial Shenanigans* + Beneish M-Score + forensic accounting principles

Data: SEC EDGAR 10-K (Fiscal year ended December 31, 2025) + Yahoo Finance

Auditor: Ernst & Young LLP — Unqualified opinion (1 critical audit matter: Provisions for returns on product sales)

One-line verdict: Moderna earns an F because operating cash flow was negative for three consecutive years, free cash flow after acquisitions has been negative for three years, and the business is in post-pandemic runoff — revenue collapsed from $18.9B in FY2022 to $1.9B in FY2025, a 90% decline. The accounting itself is clean (M-Score -3.50, accruals ratio -7.7%, auditor opinion unqualified), but the fundamental business model — a three-product commercial portfolio of COVID/RSV vaccines in a shrinking market — is burning down cash while the company still runs 35 clinical programs. Moderna holds $5.8B in cash against $1.3B in debt, so there is runway, but the $2.8B annual loss is structural, not cyclical.

From Pandemic Hero to Runoff

Moderna describes itself in the 10-K as "a biotechnology company advancing a new class of medicines made of messenger RNA (mRNA)." The 10-K discloses that Moderna "currently have three commercial products — Spikevax and mNEXSPIKE, our COVID vaccines, and mRESVIA, our vaccine against respiratory syncytial virus (RSV)." Beyond those three, the company states it has "a diverse development pipeline of 25 development candidates across our 35 development programs currently in clinical studies."

The revenue collapse is the central fact of this filing. From the MD&A: "For the year ended December 31, 2025, we recognized total revenue of $1.9 billion compared to $3.2 billion and $6.8 billion for the years ended December 31, 2024 and 2023, respectively."

Net product sales broken out by geography from the MD&A:

Europe fell from $1.35B to $50M in two years — a 96% collapse — which the MD&A attributes in Item 1A to a competitor contract: "we have been excluded from selling our COVID vaccines in many European markets due to a competitor's contract with the European Commission, which does not lapse until year-end 2026."

Net product sales by product, from MD&A:

mRESVIA, the RSV vaccine launched in Q3 2024, did only $8M in 2025 against two well-established larger competitors. From Item 1A: "For RSV vaccines, we entered a market already occupied by two larger competitors and may continue to face difficulties achieving market share."

Cash Flow: Three Straight Years of Burn

This is the first critical failure. The engine flags C1 (CFFO < NI for 3 consecutive years) as a fail. In Moderna's case the direction is actually favorable — both lines are negative, but losses and burn rates are narrowing as the company executes its cost-reduction program. The MD&A references: "If we do not successfully implement our cost efficiency and prioritization programs, we may fail to meet our cash breakeven goal."

In November 2025, Moderna entered a new $1.5B five-year term loan facility. From the MD&A: "In November 2025, we entered into a five-year term loan facility providing for up to $1.5 billion of capital to enhance our balance sheet and provide increased financial flexibility. The facility includes a $600 million initial term loan funded at closing, a $400 million delayed draw term loan facility available through November 2027, and an additional $500 million delayed draw term loan facility available through November 2028, subject to the achievement of specified regulatory milestones." This is the first time Moderna has taken on meaningful long-term debt.

The E1 fail (FCF after acquisitions negative for 3 years) is the mathematical counterpart to the C1 fail — there has been no year in which operating cash flow covered total investing needs.

Balance Sheet: Runway Still There

Liquid assets of ~$8.1B exceed debt of $1.3B by a factor of 6.2x. Retained earnings fell from $10.0B to $7.2B — the direct result of the FY2025 net loss. Total equity dropped $2.2B YoY for the same reason. Debt rose $0.6B after the new term loan draw.

At the current burn rate of ~$2B per year, pre-cost-cut, runway extends roughly 4 years before additional capital is required. This is the only reason the engine does not flag C4 (cash vs. debt) — cash coverage is strong in absolute terms.

The 18-Point Screening

Revenue Quality

All three revenue quality checks pass — receivables shrank faster than revenue (which is the correct direction in a contracting business), and the DSO of 35 days is healthy.

Expense Quality

B1 (watch): Inventory grew from $117M to $153M while COGS dropped 40.7%. For a vaccine business this is potentially concerning — inventory that does not sell becomes an obsolescence write-down (vaccines are dated product). EY's critical audit matter is specifically around returns reserve, which is closely linked to channel inventory.

B3 (watch): SG&A expense of $816M against $1,054M of gross profit = 96.6%. Nearly every dollar of gross profit is consumed by sales, general and administrative costs before R&D is even considered. The cost structure was built for a $20B+ revenue business and has not fully right-sized to a $1.9B revenue reality.

Cash Flow Quality

C1 (critical fail): Both CFFO and net income are negative across all three years — the engine's rule fires because CFFO < NI is evaluated in absolute terms; for Moderna, more negative CFFO than NI in historical years plus the three-year sequence triggers the fail. Worth noting the *direction* is improving: CFFO went from -$3.1B (2023) to -$3.0B (2024) to -$1.9B (2025).

The C3 accruals ratio of -7.7% is actually reassuring — it means the business's reported loss is more severe on an accrual basis than on a cash basis, i.e., the company is not understating losses.

Balance Sheet

D1 is a rare pass for a commercial-stage biopharma — Moderna built its mRNA platform in-house and has done minimal acquisition activity, so goodwill and intangibles are a trivial $0.1B. D2 is a watch because operating income is deeply negative, so interest coverage is meaningless as a ratio.

M&A Risk

E1 (fail): See cash flow section above. This is a mechanical restatement of the fundamental fact that Moderna has not generated cash for three years.

Beneish M-Score

The M-Score of -3.50 is well below the manipulation threshold — among the lowest in our coverage universe. This is intuitive: a company with collapsing revenue and widening losses has no accounting motivation (or mechanism) to inflate results. The M-Score is designed to detect earnings *inflation*, and Moderna's reported losses are if anything more severe than cash-basis reality. On pure manipulation risk, this is a clean report.

Critical Audit Matter: Product Return Provisions

EY identified one critical audit matter: provisions for returns on product sales. From the audit report:

"During the year ended December 31, 2025, the Company's net product sales were $1.8 billion. As explained in Note 2 of the consolidated financial statements, revenue from product sales includes estimates of variable consideration for which provisions are established, including provisions for product sales returns. Auditing the Company's measurement of provisions for returns on product sales under its contracts with customers was especially challenging because (1) the estimate relies on management's assumptions regarding inventory remaining in the distribution channel as of the balance sheet date that may be subject to return in future periods, as well as projected market demand, and (2) the Company has limited historical returns on which to base its assumptions."

EY's audit procedures included "testing the accuracy and completeness of the underlying data used in the calculations" and "inspected agreements with significant customers to validate the rights of return... reviewed inventory on hand-reporting from significant customers around the balance sheet date and subsequent to the balance sheet date and inspected vaccination data from third-party sources after the balance sheet date." EY has served as Moderna's auditor since 2014.

The product returns risk is real: vaccine demand is seasonal and hard to forecast, the CDC's Advisory Committee on Immunization Practices (ACIP) recommendations can shift eligibility overnight, and Moderna's MD&A disclosed a 2024 adjustment of "approximately $216 million... reflecting a reduction in prior year provision estimates, primarily related to returns and chargebacks for the previous COVID vaccine season." A similar adjustment did not repeat in 2025 but the estimation challenge did not go away.

Key Risks from Item 1A

1. Regulatory uncertainty and shifting vaccine guidance. From Item 1A: "In 2025, changes at U.S. regulatory agencies impacted policies and priorities related to our industry. For example, changes in FDA regulatory policies, post-marketing safety monitoring, and evidentiary expectations, as well as CDC and Advisory Committee on Immunization Practices (ACIP) recommendations regarding eligibility, target populations, and vaccination practices, may have affected and may continue to affect demand for our vaccines."

2. European market exclusion. From Item 1A: "we have been excluded from selling our COVID vaccines in many European markets due to a competitor's contract with the European Commission, which does not lapse until year-end 2026." European product sales fell from $1.35B (2023) to $50M (2025).

3. RSV competition. From Item 1A: "For RSV vaccines, we entered a market already occupied by two larger competitors and may continue to face difficulties achieving market share." mRESVIA did only $8M in FY2025.

4. Cost efficiency execution risk. From Item 1A: "If we do not successfully implement our cost efficiency and prioritization programs, we may fail to meet our cash breakeven goal."

5. Pipeline pruning risk. From Item 1A: "as we pursue development of our prioritized programs, we may forego or delay pursuit of other opportunities that could prove to have greater commercial potential. If our prioritized programs are unsuccessful, or not as successful as others could have been, we may be unable to realize a sustainable return on our investments."

6. Manufacturing overbuild. The Norwood, Massachusetts drug product manufacturing expansion ("Construction for the new drug product manufacturing capability has commenced, with completion targeted in the first half of 2027") continues despite the revenue collapse.

Altman Z-Score and F-Score

The Z-Score of 5.29 is comfortably in the safe zone, driven entirely by the working capital and cash position. EBIT contribution is negative but the other components (equity-to-debt, working capital, retained earnings) remain positive. The F-Score of 0.57 is among the lowest in our coverage — with collapsing revenue and no acquisition activity, there are no components that flag.

Summary

Grade: F. Two fails, both cash-flow related.

Moderna's F grade is about cash burn, not accounting quality. The company's reported numbers look consistent with reality: losses are larger than cash burn (good sign against manipulation), DSO is 35 days (tight), M-Score -3.50 (very clean), accruals -7.7% (conservative). EY's single critical audit matter on returns provisions is the appropriate area for auditor focus given the channel inventory dynamics.

The problem is the business, not the books. Revenue collapsed from $18.9B in FY2022 to $1.9B in FY2025. Europe is essentially zero until the EU Commission contract lapses at the end of 2026. RSV launched into competition from GSK and Pfizer and captured $8M of sales. The cost structure assumed a $20B+ franchise. The company is burning $2B per year with $8B of liquidity and a new $1.5B backup credit line.

The path forward is pipeline: 35 clinical programs, with the mRNA-4157 individualized cancer vaccine in Phase 3 with Merck (Moderna receives royalties) and a seasonal flu vaccine with a PDUFA goal date of August 5, 2026. The earnings quality of Moderna's financials is fine; the earnings themselves depend on programs that may not generate revenue for several more years.

**Disclaimer**: This report is based on Moderna's FY2025 10-K (SEC EDGAR) and public financial data. This is NOT investment advice.

Data: SEC EDGAR 10-K (Fiscal year ended December 31, 2025) + Yahoo Finance

Auditor: Ernst & Young LLP (Unqualified opinion, 1 critical audit matter: Provisions for returns on product sales)